- In an interview with Reuters, Genzyme's (NASDAQ:SNY) (NASDAQ:GCVRZ) chief of its multiple sclerosis franchise Bill Sibold says his firm intends to be a leader in the field via new products and acquisitions.
- He is confident about the commercial success of Lemtrada (alemtuzumab) and Aubagio (teriflunomide). Analysts forecast Lemtrada's peak sales at $437M and Aubagio's at $1.2B.
- Predictably, no word on acquisition targets, but he says that they are looking to acquire truly innovative products. "If the opportunity is the right opportunity, we'll evaluate it...We're well-resourced to execute our strategy."
- The firm expects an FDA decision on its revised marketing app for Lemtrada in Q4. The agency rejected its initial application last December.